Introduction: The Shift Toward Patient-Centered Endpoints in Diabetes Research

Over the past decade, the landscape of diabetes clinical trials has undergone a meaningful transformation. While hemoglobin A1c (HbA1c), fasting plasma glucose, and time-in-range remain essential laboratory endpoints, researchers and regulators alike now recognize that these biomarkers tell only part of the story. A growing body of evidence demonstrates that patient-reported outcomes (PROs)—direct reports from patients about their health status, symptoms, and well-being—are indispensable for evaluating the true value of diabetes therapies. This article explores the expanding role of PROs in diabetes trials, detailing their types, benefits, challenges, regulatory context, and future directions.

The impetus behind this shift is simple: diabetes is a lifelong condition that profoundly affects every aspect of daily life, from diet and exercise to emotional health and social functioning. A treatment that lowers glucose but causes debilitating side effects, burdensome dosing, or significant financial cost may not be acceptable to patients. PROs provide the missing link between biological efficacy and real-world tolerability, enabling a more holistic evaluation of therapy.

Why PROs Matter: Beyond Traditional Clinical Endpoints

Traditional clinical endpoints in diabetes trials are objective, quantifiable, and well validated. However, they do not capture the patient’s subjective experience. HbA1c, for example, reflects average glucose over two to three months but says nothing about hypoglycemia, quality of sleep, injection pain, or emotional distress. Without PROs, a trial may show outstanding glucose control while masking significant negative impacts on quality of life.

The U.S. Food and Drug Administration (FDA) has explicitly endorsed PROs in its regulatory guidance, stating that PROs can be used to support labeling claims provided they are measured with reliable, validated instruments. According to the FDA’s 2009 PRO guidance, data collection instruments should reflect the concepts most important to patients and be psychometrically sound. This regulatory backing has accelerated the integration of PROs into Phase II, III, and IV studies.

Types of Patient-Reported Outcomes in Diabetes Trials

PROs are not monolithic; they encompass a wide range of domains. Researchers typically select instruments based on the specific treatment, population, and study objectives. The following are the most common categories and examples of validated tools used in diabetes research.

HRQoL is the most frequently assessed PRO domain in diabetes trials. Instruments such as the Diabetes Quality of Life (DQOL) measure and the Short Form-36 (SF-36) are widely used. The DQOL captures satisfaction with treatment, impact of diabetes, and diabetes-related worry. The SF-36 provides a generic assessment of physical and mental health functioning. Studies show that improvements in HRQoL are often independent of metabolic improvements, highlighting the importance of measuring both.

Symptom Burden and Severity

Diabetes and its treatments produce a variety of symptoms: fatigue, neuropathy, blurred vision, hypoglycemic events, gastrointestinal issues, and injection-site reactions. PROs like the Diabetes Symptom Checklist—Revised (DSC-R) or the Hypoglycemia Fear Survey (HFS) allow patients to report the frequency and severity of these experiences. Capturing symptom burden helps clinicians differentiate between therapies that offer comparable glycemic control but diverge in side-effect profiles.

Treatment Satisfaction and Preference

Patient satisfaction with a treatment regimen is a strong predictor of long-term adherence. Tools such as the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Insulin Treatment Satisfaction Questionnaire (ITSQ) assess aspects like convenience, flexibility, and perceived efficacy. High satisfaction correlates with better persistence and outcomes.

Psychological Well-Being and Diabetes Distress

Diabetes distress—distinct from clinical depression—refers to the emotional burden of managing the condition. The Problem Areas in Diabetes (PAID) scale and the Diabetes Distress Scale (DDS) are validated measures that capture feelings of helplessness, frustration, and worry. Trials of continuous glucose monitors (CGMs) and automated insulin delivery systems increasingly include these PROs to understand whether technology reduces or exacerbates emotional burden.

Medication Adherence and Self-Care Behaviors

Adherence to medication and self-monitoring is notoriously difficult in diabetes. PROs such as the Self-Care Inventory (SCI-R) and the Medication Adherence Report Scale (MARS) ask patients to report their own behavior. While subject to recall bias, these tools provide valuable context for interpreting efficacy results—a drug may appear less effective because patients did not take it as prescribed.

Benefits of Including PROs: From Evidence to Practice

Incorporating PROs delivers tangible advantages across the drug development lifecycle and into clinical practice.

Enhanced Patient-Centered Care

PROs ensure that the patient’s voice is systematically heard. When treatment decisions are informed by what matters most to patients—such as avoiding hypoglycemia, limiting weight gain, or reducing injection frequency—the resulting care aligns with individual priorities. This shared decision-making approach improves trust and engagement.

Differentiation Among Therapies

In a crowded diabetes marketplace, PROs can distinguish products that otherwise show similar HbA1c reductions. For example, a GLP-1 receptor agonist that causes less nausea may have a better PRO profile than a comparator, leading to higher adherence and patient retention in both trials and real-world settings.

Support for Regulatory and Reimbursement Decisions

Regulatory agencies in the U.S. and Europe increasingly consider PRO data. A therapy that improves both glycemic control and PROs may earn labeling claims such as “improves quality of life” or “reduces diabetes-related distress.” Similarly, health technology assessment bodies like NICE in the UK use PRO evidence to evaluate cost-effectiveness and recommend coverage.

Identification of Unmet Needs

PROs can reveal issues that clinicians may overlook. For instance, patients with type 2 diabetes often report high levels of fatigue and cognitive “fog.” Such symptoms may be dismissed but, when captured via PROs, can drive further investigation into mechanisms and potential interventions.

Improved Trial Retention and Diversity

Trials that incorporate PRO collection and provide feedback to participants sometimes see higher retention rates. Additionally, digital PRO (ePRO) tools make it easier to include patients from remote or underrepresented areas, enhancing generalizability.

Challenges in Implementing PROs in Diabetes Trials

Despite their promise, PROs present several methodological and operational challenges that must be carefully managed.

Selection and Validation of Instruments

Not all PRO instruments are suitable for every population. A scale validated in English-speaking adults may not be culturally appropriate for a multi-ethnic trial. Researchers must ensure linguistic and psychometric validation for each target language and cultural context. The ISPOR Good Practices for Outcomes Research provides guidelines for selecting and translating PROs.

Response Shift and Adaptation

Patients may change their internal standards over time (response shift). For example, after starting a new therapy, a patient might recalibrate their perception of “acceptable” symptoms. This can obscure true treatment effects. Statistical methods like then-test or structural equation modeling can help adjust for response shift but add complexity.

Missing Data and Bias

PRO data are particularly vulnerable to missing responses if patients become ill, drop out, or skip visits. High missing rates can bias results. Predefined strategies for handling missing data—such as mixed models for repeated measures (MMRM) or multiple imputation—are essential.

Burden of Collection

Frequent or lengthy PRO questionnaires can burden patients, leading to incomplete or rushed answers. Electronic PRO (ePRO) tools, with adaptive questioning and reminders, can reduce burden. The shift to ePRO also enables real-time monitoring and improves data quality.

Interpreting Subjective Responses

Unlike a lab value, a PRO score has no absolute threshold for “good” or “bad.” Researchers must define minimal clinically important differences (MCIDs) a priori. Anchor-based and distribution-based methods are used, but MCIDs can vary across populations.

Regulatory and Industry Perspectives

The FDA’s Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims remains foundational. The guidance outlines a rigorous framework for developing and validating PRO instruments, including qualitative patient input, item generation, psychometric testing, and documentation. The European Medicines Agency (EMA) similarly endorses PROs but emphasizes patient relevance and interpretability.

Pharmaceutical sponsors increasingly view PROs as a competitive advantage. Many companies now have dedicated PRO teams that collaborate on trial design from the outset. Public repositories such as ClinicalTrials.gov show that more than 60% of diabetes interventional studies registered in the last three years include at least one PRO endpoint, up from roughly 30% a decade ago.

Digital and Technological Advancements in PRO Collection

Technology is reshaping how PROs are collected and used. Traditional paper questionnaires are giving way to ePRO platforms on smartphones, tablets, or web portals. Benefits include time-stamped responses, branching logic to reduce burden, and immediate data availability. In diabetes, wearables and continuous glucose monitors can be paired with ePRO diaries, allowing researchers to correlate glucose profiles with real-time symptoms and mood.

Artificial intelligence and natural language processing are being explored to analyze open-ended patient comments captured alongside structured PROs. This could unlock rich qualitative data that complements quantitative scores. However, data privacy and security remain paramount; platforms must comply with HIPAA and GDPR regulations.

Cultural and Demographic Considerations

Diabetes disproportionately affects minority and underserved populations. PRO instruments developed primarily in white, English-speaking, educated populations may not capture culturally specific concerns. For instance, eating behaviors, diabetes-related stigma, and family involvement differ across cultures. Engaging community advisory boards and using cognitive debriefing interviews ensures that PROs are relevant and understandable. Failure to adapt PROs can lead to biased results and perpetuate health disparities.

Future Directions: Where PROs in Diabetes Are Headed

Standardized Core Outcome Sets

Initiatives like the Core Outcome Measures in Effectiveness Trials (COMET) and International Consortium for Health Outcomes Measurement (ICHOM) are working toward a minimum set of PROs for diabetes trials. Standardization would facilitate cross-trial comparisons and meta-analyses.

Dynamic and Personalized PRO Assessment

With advances in mobile health, PROs can be administered adaptively. For example, a patient experiencing hypoglycemia may be prompted to answer additional questions about fear and impact, while a patient without events skips those items. Computerized adaptive testing (CAT) can reduce questionnaire length while maintaining precision.

Integration with Real-World Evidence (RWE)

Electronic health records (EHRs) and claims databases increasingly incorporate PRO data. Linking trial-derived PRO instruments with real-world collection could validate findings in broader populations and support label extensions.

Patient-Reported Outcomes as Primary Endpoints

To date, PROs are nearly always secondary endpoints. However, for treatments targeting symptoms or quality of life—such as therapies for painful diabetic neuropathy or non-insulin alternatives in early type 2 diabetes—there is a growing movement to designate PROs as primary. This would require even rigorous validation and statistical planning but would empower patients to directly influence approval decisions.

Conclusion: A Patient-Centric Future

The integration of patient-reported outcomes in diabetes clinical trials is no longer an afterthought—it is a strategic necessity. By capturing what matters most to patients, PROs transform trials from mechanistic efficacy studies into evaluations of real-world value. The path forward involves continued investment in culturally sensitive, psychometrically robust instruments; technological innovation to ease collection; and regulatory frameworks that reward patient-centered evidence. As diabetes care becomes ever more personalized, PROs will remain at the forefront, ensuring that the voices of those living with the condition guide the development of safer, more tolerable, and truly effective therapies.